Increasing attention has been paid to decentralized health care systems in order to evaluate health outcomes. In Brazil, state-run pharmaceutical assistance falls within the scope of a decentralized health care system, also known as SUS (Brazilian Unified Health System). The research intends to shed light on pharmaceutical policy implementation in Brazil through SUS, and argues that it can be used as a guide for institutional reform. This will be accomplished by reviewing the weaknesses and strengths of the SUS decentralized structure as revealed in the pharmaceutical policy responses to HIV/AIDS and tuberculosis. Under the assumption of pharmaceutical assistance improvement conditioned to re-centralization of some functions; it can be argued that a balanced approach to decentralization is more desirable to the pharmaceutical sector than the existing decentralized system. The aim of this study is to highlight the advantages of establishing a hybrid system for pharmaceutical assistance.

Thesis (Ph. D.)--University of Melbourne, Dept. of Political Science, 1997. / Typescript (photocopy). Includes bibliographical references (leaves 282-313).

Thesis (Ph. D.)--Rutgers University, 2010. / "Graduate Program in Global Affairs." Includes bibliographical references (p. 349-376).

Thesis (Ph. D.)--Memorial University of Newfoundland, 2005. / Restricted until May 2006. Includes bibliographical references (leaves 187-207).

While a significant amount of research has been produced in Canada on direct-to-consumer advertising (DTCA) of prescription drugs in general, very little work has been undertaken specifically with regard to the role of social media and emerging Internet technologies. While Health Canada has reaffirmed that existing DTCA regulations apply to new Internet and social media technologies, there are several unique features of these technologies that make the application of existing regulations an uncertain process. Further, given the difficulties Health Canada has faced in directly regulating DTCA in traditional media, there is significant skepticism around whether government regulators have the resources or political will to effectively monitor new digital media. Consequently, independent third party oversight and industry self-regulation may play an important role in regulating digital channels. Finally, regulators should not simply be limited to regulating online DTCA; social media is equally available to government for use in health promotion.

While a significant amount of research has been produced in Canada on direct-to-consumer advertising (DTCA) of prescription drugs in general, very little work has been undertaken specifically with regard to the role of social media and emerging Internet technologies. While Health Canada has reaffirmed that existing DTCA regulations apply to new Internet and social media technologies, there are several unique features of these technologies that make the application of existing regulations an uncertain process. Further, given the difficulties Health Canada has faced in directly regulating DTCA in traditional media, there is significant skepticism around whether government regulators have the resources or political will to effectively monitor new digital media. Consequently, independent third party oversight and industry self-regulation may play an important role in regulating digital channels. Finally, regulators should not simply be limited to regulating online DTCA; social media is equally available to government for use in health promotion.

This research involved a rigorous implementation of the conceptual framework of Australia's National Strategy for Quality Use of Medicines through a planned sequence of studies across a large defined geographical region to test the hypothesis that: The National Strategy for Quality Use of Medicines can be used to design, implement and evaluate a research program to achieve sustained improvement in health care in a regional setting.

Orientador: Pedro Luiz Barros Silva / Dissertação (mestrado) - Universidade Estadual de Campinas, Instituto de Economia / Made available in DSpace on 2018-08-20T09:06:11Z (GMT). No. of bitstreams: 1 Rodrigues_CamilaLins_M.pdf: 2244031 bytes, checksum: 943fc02d25c2a13cb8bbb7920d5e79a0 (MD5) Previous issue date: 2012 / Resumo: As nações desenvolvidas conseguiram consolidar tanto a construção de Sistemas de Proteção Social, quanto a construção de Sistemas de Inovação. Por um lado, políticas sociais em áreas fundamentais e estratégicas como saúde, educação e previdência ganharam espaço privilegiado em suas agendas de governo. Por outro lado, esses países realizaram processos bem sucedidos de catching up, consolidando suas bases industriais e se tornando líderes mundiais na produção de ciência e tecnologia. Outra realidade, no entanto, vivem os países periféricos. Ao mesmo tempo em que ainda caminham no sentido de construir um Sistema de Proteção Social, com a persistência de problemas sociais graves, esses países também apresentam dependência econômica e atraso tecnológico em relação aos países centrais. No caso específico do Brasil, o setor saúde, representado pelo seu complexo industrial, pode ser um importante componente estratégico para o desenvolvimento simultâneo do Sistema de Proteção Social e do Sistema de Inovação, condição necessária para que o país abandone sua condição periférica. Avanços nas indústrias deste complexo podem, de um lado, trazer benefícios econômicos para o país e, de outro, atender as necessidades de saúde da população, amenizando os agravos sociais existentes. Essa dissertação busca, a partir de um recorte analítico do conceito de complexo industrial da saúde, elucidar o papel específico que a indústria farmacêutica e o governo (através da construção de uma Política Nacional de Medicamentos) possuem no processo de desenvolvimento do sistema de saúde brasileiro e na dinâmica local de inovação. As políticas de medicamentos desenvolvidas no Brasil ao longo do século XX são analisadas sob uma perspectiva histórica, contextualizando-se a discussão a partir do processo de construção das políticas de saúde no país. Procura-se compreender como escolhas do passado inviabilizaram a construção de uma Política Nacional de Medicamentos efetiva, e como a ocorrência de eventos recentes como a criação do Sistema Único de Saúde (SUS) e as transformações da indústria farmacêutica internacional podem contribuir para uma mudança positiva de cenário / Abstract: The developed countries were successful in the consolidation of Social Protection Systems as well as Innovation Systems. On one hand, Social Policies related to essential and strategic areas such as health, education and social security have gotten a privileged space at the governments' agenda. On the other hand, these countries established outstanding processes of catching up, consolidating their industrial bases and becoming world leaders in science and technology statistics. However , the poor countries experience another reality. While they are still trying to build a Social Protection System, with the persistence of heavy social problems, these countries face economic dependency and technologic delay when compared with developed countries. Specifically, Brazil?s health area, represented by its industrial complex, could be an important strategic component for both Social Protection and Innovation Systems development, necessary condition for the country to leave its poverty condition. Progress in these industrial complex, on one hand, can provide economics benefits to the country, and, on the other hand, can answer the population health needs, reducing the social damages existent. This dissertation searches, from an analytical view of industrial health complex concept, to elucidate the specific pharmaceutical industry and government?s role (through a National Pharmaceutical Policy building) at the development of brazilian health system and local dynamic innovation. The Pharmaceutical Policies developed in Brazil along XX century are analyzed under a historical perspective, contextualizing the discussion from the health policies building process in the country. It seeks to understand how decisions made in the past contributed to an inefficient National Pharmaceutical Policy, and how the occurrence of recent events, like the creation of the SUS (Sistema Único de Saúde) and the transformations of the international pharmaceutical industry can add to a positive scenery change / Mestrado / Economia Social e do Trabalho / Mestre em Desenvolvimento Econômico

No description available.

No description available.